share_log

東陽光長江藥業：聯合公告(1)以吸收合併宜昌東陽光長江藥業股份有限公司之方式由廣東東陽光藥業股份有限公司對宜昌東陽光長江藥業股份有限公司作出附前提條件的私有化之建議(2)建議特別股息(3)建議撤銷上市(4)恢復買賣

HEC CJ PHARM: JOINT ANNOUNCEMENT (1) PROPOSED PRE-CONDITIONAL PRIVATISATION OF YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. BY SUNSHINE LAKE PHARMA CO., LTD. BY WAY OF MERGER BY ABSORPTION OF YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. (2) PROPOSED SPECIAL DIVIDE

Hong Kong Stock Exchange ·  May 10 21:28
Summary by Futu AI
廣東東陽光藥業股份有限公司（東陽光藥）與宜昌東陽光長江藥業股份有限公司（長江藥業）宣佈，將通過吸收合併方式實施私有化，並計劃將東陽光藥H股以介紹方式在香港聯合交易所主板上市。合併協議於2024年5月10日簽訂，待相關前提條件及生效條件達成後，長江藥業將從聯交所除牌，而東陽光藥將承接長江藥業所有資產、負債、權益及業務。換股股東將按每股被註銷的換股H股獲得0.263614股新東陽光藥H股，並獲特別股息每股1.50港元。此次合併旨在提升公司整體運營效率，擴大市場規模，並提升股東回報。合併完成後，東陽光藥將成為具有全面一體化實力的研發驅動型國際化製藥公司。
廣東東陽光藥業股份有限公司（東陽光藥）與宜昌東陽光長江藥業股份有限公司（長江藥業）宣佈，將通過吸收合併方式實施私有化，並計劃將東陽光藥H股以介紹方式在香港聯合交易所主板上市。合併協議於2024年5月10日簽訂，待相關前提條件及生效條件達成後，長江藥業將從聯交所除牌，而東陽光藥將承接長江藥業所有資產、負債、權益及業務。換股股東將按每股被註銷的換股H股獲得0.263614股新東陽光藥H股，並獲特別股息每股1.50港元。此次合併旨在提升公司整體運營效率，擴大市場規模，並提升股東回報。合併完成後，東陽光藥將成為具有全面一體化實力的研發驅動型國際化製藥公司。
GUANGDONG SUNSHINE PHARMACEUTICAL CO., LTD. (EAST SUN PHARMACEUTICALS) AND YICHANG DONG SUN CHANGJIANG PHARMACEUTICAL CO., LTD. (CHANGJIANG PHARMACEUTICALS) ANNOUNCED THAT THEY WILL BE PRIVATIZED BY ABSORPTION MERGER AND PLAN TO LIST DONG SUN H SHARES IN AN INTRODUCTORY WAY ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE. The merger agreement was signed on May 10, 2024. After the relevant preconditions and conditions are met, Changjiang Pharmaceutical will delist from the Exchange, and Dongxiang Pharmaceutical will assume all assets, liabilities, interests and business of Changjiang Pharmaceutical. Exchange shareholders will receive 0.263614 shares of XINDONG SUNSHINE MEDICINE H Shares for each share withdrawn and receive a special dividend of HK$1.50 per share. The merger aims to improve the company's overall operating efficiency, expand market size, and improve shareholder returns. Upon completion of the merger, Dongsun Pharmaceuticals will become a research-driven, internationalized pharmaceutical company with comprehensive integrative capabilities.
GUANGDONG SUNSHINE PHARMACEUTICAL CO., LTD. (EAST SUN PHARMACEUTICALS) AND YICHANG DONG SUN CHANGJIANG PHARMACEUTICAL CO., LTD. (CHANGJIANG PHARMACEUTICALS) ANNOUNCED THAT THEY WILL BE PRIVATIZED BY ABSORPTION MERGER AND PLAN TO LIST DONG SUN H SHARES IN AN INTRODUCTORY WAY ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE. The merger agreement was signed on May 10, 2024. After the relevant preconditions and conditions are met, Changjiang Pharmaceutical will delist from the Exchange, and Dongxiang Pharmaceutical will assume all assets, liabilities, interests and business of Changjiang Pharmaceutical. Exchange shareholders will receive 0.263614 shares of XINDONG SUNSHINE MEDICINE H Shares for each share withdrawn and receive a special dividend of HK$1.50 per share. The merger aims to improve the company's overall operating efficiency, expand market size, and improve shareholder returns. Upon completion of the merger, Dongsun Pharmaceuticals will become a research-driven, internationalized pharmaceutical company with comprehensive integrative capabilities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.